Company Announcements

Classification of Parmantier & Cie. GmbH to CLINUVEL Pharmaceuticals Limited

Company Name:	CLINUVEL Pharmaceuticals Limited
ISIN:	AU000000CUV3
Reason for the research:	Update
Recommendation:	Buy
from:	30.09.2025
Target price:	26.50 AU$
Target price on sight of:	12 month
Last rating change:	none
Analyst:	Thomas Schiessle, Daniel Großjohann

CLINUVEL strengthens global position with tariff advantage and Nasdaq uplisting

Frankfurt am Main, 30 September 2025. Parmantier & Cie highlights in its latest research note the strategic decisions taken by CLINUVEL Pharmaceuticals Limited (ASX: CUV; Nasdaq ADR: CLVLY), combining operational resilience with a clear capital markets strategy. The company is positioning itself strongly for its next phase of growth.

A key element of CLINUVEL’s strategy is its effective protection against potential trade barriers in the United States. While many international pharma and biotech companies are facing the impact of looming import tariffs, CLINUVEL remains largely unaffected thanks to its forward-looking production and logistics setup. By expanding its own manufacturing capacities in the US, the company has effectively shielded itself from potential 100% import tariffs. This tariff resilience not only safeguards margins and supply chains but also provides a clear competitive advantage in an increasingly protectionist environment.

At the same time, CLINUVEL is advancing the internationalisation of its capital markets presence. By the end of 2025, the company plans to upgrade its American Depositary Receipt (ADR) programme from Level I to Level II on the Nasdaq. This move will meet the more demanding regulatory requirements of US capital markets and open the door to new investor groups, particularly institutional investors in North America. With more than 250 listed companies and a market capitalisation of approximately USD 1.22 trillion, the Nasdaq Biotechnology Index (NBI) is the world’s leading marketplace for biotech firms. Uplisting to Level II will significantly increase CLINUVEL’s visibility in the US and broaden its investor base — without the need for a capital increase.

The timing of this step is well chosen. The ongoing interest rate cuts by the US Federal Reserve are creating a supportive environment for equity markets, particularly for biotech stocks. CLINUVEL is taking advantage of this momentum to strengthen its presence in the US capital markets and to further implement its global growth strategy, while maintaining its primary listing on the Australian Securities Exchange (ASX).
By combining operational robustness against tariff risks with the upcoming Nasdaq uplisting, CLINUVEL is sending a clear strategic signal. The company is uniting stability with expansion potential, laying the foundation for sustainable international growth.

Full research report available at:
Bloomberg ; FactSet ; LSEG
Online: https://www.parmantiercie.com/research

About PARMANTIER & CIE. GmbH
PARMANTIER & CIE. is a modern merchant bank based in Frankfurt am Main. The firm advises companies on all aspects of financing – equity, debt, and hybrid instruments – and also invests its own capital in listed and private companies. PARMANTIER & CIE. stands for integrity, foresight, and tailored financing solutions with entrepreneurial commitment.
 

You can download the research here: 25_09_30_CUV_PCR_Update_FY-2025-Report_english

Contact for questions:
Parmantier & Cie. Research
Hungener Straße 6
60389 Frankfurt am Main
E-mail: info@parmantiercie.com